Objective: We evaluated the clinical efficacy of sacubitril/valsartan in a group of ambulatory patients with heart failure (HF) with reduced ejection fraction (HFrEF) referred to our HF clinic.
Methods: Patients (n = 29; 72% males; mean age 76 years) with HFrEF in New York Heart Association (NYHA) classes II-III were included in the present study. We evaluated clinical as well as echocardiographic parameters (e.g. haemodynamics, such as blood pressure and heart rate, metabolic status, echocardiographic ventricular volumes and ejection fraction [EF]), at baseline and after 6 months of treatment with sacubitril/valsartan.
Results: After 6 months of sacubitril/valsartan treatment, several parameters were significantly improved. For example, EF and ventricular volumes (both diastolic and systolic) and atrial dimensions, as well as NYHA functional class (only 1 patient was still in NYHA class III) and renal impairment improved. There was no hospitalization for HF or other causes during the 6 month follow-up and no patient died.
Conclusions: Based on our real-life experience, in HFrEF patients with NYHA class II-III, the new angiotensin receptor-neprilysin inhibitor (ARNi) sacubitril/valsartan was effective in improving HF management, both from the clinical and the echocardiographic perspective.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/03007995.2019.1576481 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhanced recovery in type A aortic dissection evaluating the efficacy and feasibility of early myocardial reperfusion.
Front Cardiovasc Med
January 2025
Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, China.
Background: This study investigates the feasibility and early outcomes of early myocardial reperfusion in patients with type A aortic dissection (TAAD), evaluating its effectiveness and potential benefits compared to traditional cardioplegic arrest techniques.
Methods: A retrospective analysis was conducted on 168 patients diagnosed with TAAD who underwent surgery at the General Hospital of the Northern Theater Command in China from January 2021 to July 2024. Patients were divided into two groups: early myocardial reperfusion (EMR group, = 66) and cardioplegic arrest (CA group, = 102).
Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial.
Front Cardiovasc Med
January 2025
Cardiology Service, Hospital Universitario de La Princesa, Madrid, Spain.
Introduction: Vericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. This study assessed the real-world use of vericiguat.
Material And Methods: This cross-sectional, prospective and multicenter registry (VERISEC) included 776 patients from 43 centres in Spain between December 2022 and October 2023.
The effect of thermoelectric craniocerebral cooling device on protecting brain functions in post-cardiac arrest syndrome.
Front Cardiovasc Med
January 2025
Department of Anesthesiology and Reanimation, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Türkiye.
Aim: This study aimed to protect brain functions in patients who experienced in-hospital cardiac arrest through the application of local cerebral hypothermia. By utilizing a specialized thermal hypothermia device, this approach sought to mitigate ischemic brain injury associated with post-cardiac arrest syndrome, enhance survival rates, and improve neurological outcomes as measured by standardized scales.
Methods: A prospective, single-center cohort study was conducted involving patients aged ≥18 years who experienced in-hospital cardiac arrest and achieved return of spontaneous circulation (ROSC).
Peripartum cardiomyopathy management: insights from a Latin American case report.
Arch Peru Cardiol Cir Cardiovasc
December 2024
Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru. Universidad San Ignacio de Loyola Vicerrectorado de Investigación Universidad San Ignacio de Loyola Lima Peru.
Peripartum cardiomyopathy (PPCM) is a potentially life-threatening condition that can occur during the late pregnancy or puerperium. A 31-year-old woman with a recent twin pregnancy presented with heart failure symptoms nine days postpartum. On admission, she had volume overload and hemodynamic compromise, which was rapidly reversed with inotropic levosimendan support.
View Article and Find Full Text PDFSurgical treatment of anomalous aortic origin of the coronary artery in paediatric patients: a Chinese single-center experience.
BMC Surg
January 2025
Department of Cardiothoracic Surgery, Heart Center, School of Medicine, Shanghai Children's Medical Center, Shanghai Jiaotong University, Shanghai, China.
Purpose: An anomalous aortic origin of the coronary artery (AAOCA) is a rare congenital heart disease. Some high-risk anatomical structures are at risk of inducing cardiogenic shock or even sudden death. This article summarizes our surgical experience with AAOCA in paediatric patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!